secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0000950170-23-021505
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio Q1 net loss $7.5M, cash $10.9M; INB-100 achieves 100% CR in leukemia trial
--------------------------------------------------------------------------------

- Q1 net loss $7.5M ($0.30/sh); cash $10.9M at Mar 31; raised $9.9M via ATM after quarter end.
- INB-100 Phase 1: 100% complete remissions in 7 evaluable leukemia patients; all alive; selected RP2D.
- FDA orphan drug designation for INB-400 and INB-410 for malignant gliomas, including GBM.
- INB-200 Phase 1 data selected for oral abstract at ASCO 2023; new preclinical data in ovarian cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000095017023021505/0000950170-23-021505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000095017023021505/inab-20230512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer